CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics)

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameCD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A